• 1
    Warren JR & Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i: 12735.
  • 2
    International Agency for Research on Cancer. Schistosomes liver flukes and Helicobacter pylori IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 61. Lion, France: IARC, 1994.
  • 3
    Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 126771.
  • 4
    Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 14427.
  • 5
    Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 507.
  • 6
    Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett’s esophagus. Digestion 2000; 62: 959.
  • 7
    Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett’s esophagus. Am J Gastroenterol 2000; 95: 220611.
    Direct Link:
  • 8
    Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 101621.DOI: 10.1016/s0140-6736(98)04206-8
  • 9
    Yeomans ND. New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998; 104: 56S61S.DOI: 10.1016/s0002-9343(97)00213-1
  • 10
    Blaser MJ. Helicobacter pylori eradication and its implications for the future. Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 1037.
  • 11
    Blaser MJ. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease. J Infect Dis 1999; 179: 152330.DOI: 10.1086/314785
  • 12
    Correa P, Willis D, Allison M, Gerszten E. Helicobacter pylori in pre-Colombian mummies. Gastroenterology 1998; 114: A956: G3919.
  • 13
    Wang G, Ge Z, Rasko DA, Taylor DE. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol Microbiol 2000; 36: 118796.DOI: 10.1046/j.1365-2958.2000.01934.x
  • 14
    Graham DY. Can therapy even be denied for helicobacter pylori infection? Gastroenterology 1997; 113 (Suppl.): S1137.
  • 15
    Genta RM, Lew GM, Graham DY. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6: 2819.
  • 16
    Valle J, Seppala K, Sipponen P, Kosunen T. Disappearence of gastritis after eradication of Helicobacter pylori. A morphometric study. Scand J Gastroenterol 1991; 26: 105765.
  • 17
    Tepes B, Kavcic B, Zaletel LK, et al. Two-to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 188: 249.DOI: 10.1002/(sici)1096-9896(199905)188:1<24::aid-path316>;2-6
  • 18
    Zerbib F, Lenk C, Sawan B, et al. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol 2000; 12: 71925.
  • 19
    Howden CW. What causes Helicobacter pylori-negative non-NSAID-related ulcers. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori Basic Mechanisms to Clinical Cure 2000. London: Kluwer Academic Publishers, 2000, pp. 33946.
  • 20
    Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120: 97781.
  • 21
    Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 5969.
  • 22
    Treiber G & Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93: 10804.
    Direct Link:
  • 23
    Huang JQ, Wilkinson JM, Hunt RH. Antimicrobials accelerate healing of duodenal ulcer (DU) when given with proton pump inhibitors (PPI) or H2-receptor antagonists (H2RA): a meta-analysis. Gut 1997; 41 (Suppl. 1): A93 (Abstract).
  • 24
    Verdu EF, Armstrong D, Idstrom JP, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 11516.
  • 25
    Van Herwaarden MA, Samson M, Van Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aloment Pharmacol Ther 1999; 13: 73140.
  • 26
    Gisbert JP, Boixeda D, Martin De Argila C, Alvarez Baleriola I, Abraira V, Garcia Plaza A. Unhealed duodenal ulcers despite Helicobacter pylori eradication. Scand J Gastroenterol 1997; 32: 64350.
  • 27
    Huang JQ, Chen Y, Wilkinson J, Hunt RH. Does initial choice of Helicobacter pylori (HP) treatment regimen influence the recurrence rate of duodenal ulcer (DU)? A meta-analysis. Am J Gastroenterol 1996; 91: 1914 (Abstract 125).
  • 28
    Tygat GN. Peptic ulcer and Helicobacter pylori: eradication and relapse. Scand J Gastroenterol Suppl 1995; 210: 702.
  • 29
    Macri G, Milani S, Surrenti E, Passaleva MT, Salvatori G, Surrenti C. Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding. a long-term follow-up study. Am J Gastroenterol 1998; 93: 9257.
    Direct Link:
  • 30
    Vergara M, Casellas F, Saperas E, et al. Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage. Eur J Gastroenterol Hepatol 2000; 12: 7337.
  • 31
    Jensen DM, Cheng S, Kovacs TO, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994; 330: 3826.
  • 32
    Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 1996; 91: 154952.
  • 33
    Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995; 87: 177780.
  • 34
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 116979.
  • 35
    Forman D, Webb P, Parsonet J. H. pylori and gastric cancer. Lancet 1994; 343: 2434.
  • 36
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 673540.
  • 37
    Wang TC & Fox JG. Helicobacter pylori and gastric cancer: Koch’s postulates fulfilled? Gastroenterology 1998; 115: 7803.
  • 38
    Zhang ZW, Patahet SE, Perrett D, Katelaris PH, Domizio P, Farhing MJ. The reletion between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. Gut 1998; 43: 3226.
  • 39
    El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.DOI: 10.1038/35006081
  • 40
    El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric patients: critical role of H. pylori. Gastroenterol 2000; 118: 2230.
  • 41
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer – Second Report-Long term endoscopic follow up study. Gastroenterology 2000; 118: A726 (Abstract).
  • 42
    Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 63942.
  • 43
    Saito K, Arai K, Mori M, Kobayashi R, Ohki I. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. Gastrointest Endosc 2000; 52: 2732.
  • 44
    Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 15914.
  • 45
    Thiede C, Wundisch T, Neubauer B, et al. Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial. Recent Results Cancer Res 2000; 156: 12533.
  • 46
    Morgner A, Beyerdorffer E, Neubauer A, Stolte M. Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastoenterol Clin North Am 2000; 29: 593607.
  • 47
    Huang JQ, Sheldon A, Hunt RH. Is there a causal relationship between H.pylori infection and gastric maltoma? A meta-analysis of evidence from epidemiological studies and clinical trials. Gut 1997; 41 (Suppl. 1): A49 (Abstract).
  • 48
    Peura DA and the American Digestive Health Foundation. The report of the Digestive Health InitiativeSM international update conference on Helicobacter pylori. Gastroenteorlogy 1997; 113: S4S8.
  • 49
    Hunt RH, Fallone CA, Thomson ABR, Canadian Helicobacter Study Group. Canadian Helicobacter pylori consensus conference update: Infections in adults. Can J Gastroenterol 1999; 13: 2137.
  • 50
    European Helicobacter PyloriStudy Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 813.
  • 51
    Lam SK & Talley NJ. Helicobacter pylori consensus: Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 112.
  • 52
    Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett’s esophagus. a population-based study. Am J Gastroentrol 1999; 94: 8691.
    Direct Link:
  • 53
    El-Serag HB & Sonnenberg A. Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol 1999; 28: 1359.
  • 54
    Zheng W, Jin F, Devesa SS, Blot WJ, Fraumeni JF, Gao YT. Declining incidence is greater for esophageal than gastric cancer in Shanghai, People’s Republic of China. Br J Cancer 1993; 68: 97882.
  • 55
    The Research Group for Population-base Cancer Registration in Japan. Cancer incidence in Japan, 1985–89: re-estimation based on data from eight population-based cancer registries. Jpn J Clin Oncol 1998; 28: 5467.
  • 56
    Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 91420.
    Direct Link:
  • 57
    Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 72935.DOI: 10.1046/j.1365-2036.2000.00758.x
  • 58
    Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 4551.DOI: 10.1046/j.1365-2036.2000.00677.x
  • 59
    Murai T, Miwa H, Ohkura R, et al. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Aliment Pharmacol Ther 2000; 14 (Suppl. 1): 1615.
  • 60
    McColl K, Dickson A, El-Najumi A, El-Omar E, Kelman A. Symptomatic benefit 1–3 years post H. pylori eradication in ulcer patients: Impact of reflux disease. Gastroenterology 1999; 116: A249 (Abstract).
  • 61
    Goh KL, Parasakthi N, Cheah P-L, Prabhakeran R, Chin S-C. No occurrence of reflux oesophagitis following Helicobacter pylori eradication in duodenal ulcer patients – A 5 year endoscopic follow-up in South-East Asian patients. Gastroenterology 1999; 116: A173 (Abstract).
  • 62
    Malfertheiner P, Van Zanten S, Dent J, et al. Does cure of Helicobacter pylori infection induce heartburn. Gastroenterology 1998; 114: A212 (Abstract).
  • 63
    Axon AT, Bardhan K, Moayyedi P, Dixon MF, Brown L. Does eradication of Helicobacter pylori influence the recurence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? – A randomised double blind study. Gastroenterology 1999; 116: A117 (Abstract).
  • 64
    Tefera S, Hatlebackk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13: 91520.DOI: 10.1046/j.1365-2036.1999.00544.x
  • 65
    Wu JC, Sung JJ, Ng EK, et al. Prevalence and distibution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastro 1999; 94: 17904.
    Direct Link:
  • 66
    Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 58890.
  • 67
    El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 1815.
  • 68
    Rademaker JW & Hunt RH. Helicobacter pylori and gastric acid secretion: the ulcer link? Scand J Gastroenterol 1991; 187 (Suppl.): 717.
  • 69
    El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 1524.
  • 70
    Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA. Dose -response relationship of lansoprazole to gastric acid anti secretory effects. Aliment Pharmacol Ther 1998; 12: 3217.DOI: 10.1046/j.1365-2036.1998.00306.x
  • 71
    Chan FKL & Sung JJY. How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs? Baillire’s Clin Gastroenterol 2000; 14: 16172.
  • 72
    Huang J-Q, Lad R, Hunt RH. Role of Helicobacter pylori infection in NSAID-associated gastropathy. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori Basic Mechanisms to Clinical Cure 2000. London: Kluwer Academic Publishers, 2000, pp. 44351.
  • 73
    Chan FKL, Sung JJY, Chung SCS, et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 9759.DOI: 10.1016/s0140-6736(97)04523-6
  • 74
    Koelz HR, Bolten W, Dragosics B, et al. Primary profilaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP) -positive patients: randomized, double-blind, placebo-controlled treatment of HP infection vs omeprazole. Gastroenterology 2000; 118: A250 (Abstract).
  • 75
    Huang J-Q, Lad R, Hunt RH. Meta-analysis of the role of Helicobacter pylori in non-steroidal anti-inflammatory drug (NSAID)-associated gastropathy. Am J Gastroenterol 2000; 95: 2453 (Abstract 146).
  • 76
    Von Hertzen LC. Puzzling associations between childhood infections and the later occurrence of asthma and atopy. Ann Med 2000; 32: 397400.